2C-B-FLY: Complete Sparse-Evidence Pharmacology, Mislabeling & Safety Monograph

2C-B-FLY: Complete Sparse-Evidence Pharmacology, Mislabeling & Safety Monograph

Evidence warning: 2C-B-FLY has meaningful receptor and metabolism data but very little direct human clinical toxicology. Claims about Bromo-DragonFLY deaths, limb ischemia, multi-day duration or extreme potency should not be silently transferred to 2C-B-FLY.

Emergency safety: Seizure, dangerous overheating, severe agitation/confusion, chest pain, collapse, severe vasoconstriction/limb pain, or reduced consciousness after an unknown psychedelic requires urgent medical care—especially when the product identity may be wrong.

Quick answer

2C-B-FLY is a benzodifuran psychedelic in the phenethylamine family.

It is chemically related to—but distinct from:

• 2C-B;
• Bromo-DragonFLY;
• benzofuran entactogens such as 5-APB/6-APB.

The most defensible evidence summary is:

• direct 5-HT2 receptor pharmacology: yes;
• human-liver metabolism work: yes;
• analytically confirmed market product: yes;
• controlled human trial: no;
• robust human poisoning series: no;
• validated safe dose/half-life: no;
• direct fatality series: no in the evidence used here.

The real-world identity problem is unusually important because a far more hazardous compound—Bromo-DragonFLY—has been sold as 2C-B-FLY.

Identity

History and the “FLY” family

The FLY/DragonFLY family arose from medicinal-chemistry work exploring conformationally constrained phenethylamine psychedelics.

2C-B-FLY is a tetrahydrobenzodifuran.

Bromo-DragonFLY is a more unsaturated benzodifuran/amphetamine-like compound with a dramatically different toxicology record.

The names sound similar because of shared chemistry history—not because the drugs are interchangeable.

2C-B-FLY vs 2C-B

2C-B-FLY and 2C-B are distinct molecules.

Both interact with serotonin receptors and belong to broader psychedelic phenethylamine chemistry, but 2C-B evidence cannot automatically answer:

• 2C-B-FLY potency;
• duration;
• metabolism;
• cardiovascular toxicity;
• long-term safety.

The “FLY” ring constraint changes molecular geometry and receptor behavior.

2C-B-FLY vs Bromo-DragonFLY

This distinction is critical.

Bromo-DragonFLY is associated with:

• extraordinarily prolonged intoxication;
• powerful vasoconstriction;
• tissue ischemia/necrosis;
• fatalities.

Those findings do not describe genuine 2C-B-FLY by default.

However, they matter because Bromo-DragonFLY has been mislabeled and sold as 2C-B-FLY.

Thus, Bromo-DragonFLY belongs in this article as a product-identity hazard, not as borrowed 2C-B-FLY pharmacology.

Pharmacology

Serotonin 5-HT2 receptors

A 2015 pharmacology study found 2C-B-FLY interacted very potently with 5-HT2 receptors.

It also showed receptor activity relevant to:

• 5-HT2A;
• 5-HT2B;
• other 5-HT2 subtypes.

5-HT2A activity is central to psychedelic effects.

5-HT2B concern

In-vitro 5-HT2B agonism is scientifically relevant because chronic activation of this receptor by some drugs has been associated with cardiac-valve pathology.

What is not known is whether intermittent or repeated 2C-B-FLY exposure creates a clinically meaningful human valvulopathy risk.

The receptor signal warrants caution, not a made-up incidence estimate.

Monoamine transporters and TAAR1

The 2015 study evaluated benzofurans and 2C-B-FLY across monoamine systems.

2C-B-FLY's profile differed from classic benzofuran entactogens and was dominated by potent serotonin-receptor interaction rather than a simple MDMA-like transporter profile.

That is one reason 5-APB/6-APB evidence should not be copied onto 2C-B-FLY.

Metabolism

A 2018 study compared Bromo-DragonFLY with 2C-B-FLY in human liver systems.

2C-B-FLY underwent metabolism including:

• monohydroxylation;
• N-acetylation;
• MAO-A-related oxidative metabolism producing an aldehyde intermediate.

CYP2D6 contributed to hydroxylation.

Why this matters

CYP2D6 varies substantially between individuals and can be affected by medications.

That creates plausible interindividual variability, but the clinical effect size for 2C-B-FLY has not been measured in a human PK study.

Human pharmacokinetics: not established

No controlled human study establishes:

• bioavailability;
• time to peak;
• half-life;
• clearance;
• active metabolites;
• accumulation;
• exposure-response.

Internet duration estimates are not a substitute for human pharmacokinetic measurement.

Direct human toxicity evidence: extremely limited

The major problem with 2C-B-FLY evidence is not that toxicology proves safety.

It is that human case evidence is scarce.

CFSRE's June 2025 monograph reported:

• a confirmed 2C-B-FLY drug material;
• no toxicology cases in its dataset at that time.

That means an article should not invent a 2C-B-FLY clinical syndrome from related drugs.

The famous “2C-B-FLY” poisoning that was not 2C-B-FLY

A published toxicology conference report described a person who bought a product online as 2C-B-FLY.

Analytical follow-up identified Bromo-DragonFLY.

This is not direct evidence that 2C-B-FLY caused that toxicity.

It is evidence that research-chemical product names can be dangerously wrong.

That distinction is one of the highest-value facts on this page.

Acute risks: what can be inferred, and what cannot

Mechanistically plausible

Because 2C-B-FLY is a potent serotonergic psychedelic, plausible acute effects include:

• altered perception;
• anxiety/panic;
• agitation;
• elevated heart rate/blood pressure;
• serotonergic toxicity in excessive/mixed exposure.

Not directly quantified

Human incidence of:

• seizure;
• hyperthermia;
• severe vasoconstriction;
• cardiac complications;
• rhabdomyolysis;
• death

is not established for genuine analytically confirmed 2C-B-FLY.

These outcomes should not be imported wholesale from NBOMes or Bromo-DragonFLY.

Serotonin toxicity and interactions

No controlled interaction program exists.

Potential concern is greatest with substances that strongly increase serotonergic signaling, including:

• monoamine oxidase inhibitors;
• serotonergic stimulants;
• other powerful serotonergic psychedelics.

Because 2C-B-FLY itself has serotonergic receptor activity and MAO-related metabolism, combinations can be unpredictable.

This page does not label any combination safe.

Cardiovascular and vasoconstriction risk

2C-B-FLY's serotonergic receptor profile makes cardiovascular/vasoconstrictive effects plausible.

However, the dramatic ischemia/necrosis literature belongs primarily to Bromo-DragonFLY, not proven 2C-B-FLY.

That difference must remain explicit.

Product testing and mislabeling

The same package or online listing can contain:

• genuine 2C-B-FLY;
• Bromo-DragonFLY;
• another phenethylamine;
• a mixture.

Names such as “FLY” are not analytical confirmation.

Definitive identification can require:

• GC-MS;
• LC-MS/MS;
• LC-HRMS;
• reference standards.

Routine drug testing

Standard workplace/hospital immunoassays are not designed to identify 2C-B-FLY specifically.

A negative amphetamine or psychedelic screen does not exclude it.

Forensic identification depends on a laboratory actually including the compound in its method/library.

Tolerance

Serotonergic psychedelics can produce rapid pharmacodynamic tolerance.

No controlled human 2C-B-FLY study defines:

• onset;
• magnitude;
• cross-tolerance with LSD, 2C-B or NBOMes.

Tolerance should not be converted into a redosing strategy or safety claim.

Physical dependence, addiction and withdrawal

There is no established 2C-B-FLY physical-withdrawal syndrome comparable with opioid, alcohol or benzodiazepine withdrawal.

No population study defines 2C-B-FLY use-disorder incidence.

This does not mean repeated use is harmless.

Potential problems include:

• psychiatric destabilization;
• risky behavior;
• repeated uncertain-product exposure;
• persistent perceptual symptoms in susceptible people.

Treatment and support

There is no 2C-B-FLY-specific antidote or withdrawal medication.

Severe psychedelic toxicity is managed supportively in emergency settings based on the actual complications—such as agitation, hyperthermia, seizure, cardiovascular instability or trauma.

For problematic psychedelic use or repeated risky NPS use, substance-use and mental-health care can address the underlying behavior even without a molecule-specific medication.

Forensic interpretation

Product name is not causation

A packet labeled “2C-B-FLY” does not prove the person ingested 2C-B-FLY.

Analytical confirmation matters

The Bromo-DragonFLY mislabeling case demonstrates why a chemically confirmed result outranks a seller label.

No fatal concentration exists

There is no validated 2C-B-FLY fatal blood concentration or human lethal-dose curve.

Special populations

No controlled studies establish safety in:

• pregnancy/breastfeeding;
• adolescents;
• cardiovascular disease;
• seizure disorders;
• bipolar/psychotic disorders;
• liver disease;
• people taking CYP2D6-altering medications.

These are evidence gaps, not reassuring negatives.

Legal status — dated October 2, 2026

2C-B-FLY appears in DEA's NFLIS drug-monitoring taxonomy and U.S. forensic surveillance.

That does not by itself establish federal scheduling.

This review did not identify a federal scheduling action specifically naming 2C-B-FLY in the official U.S. sources used here.

Its relationship to controlled phenethylamines can still create legal issues under federal analogue provisions or state law depending on facts and jurisdiction.

Internationally, UNODC tracks FLY compounds within the phenethylamine NPS family; international scheduling varies by exact substance.

Myths and misconceptions

“2C-B-FLY is 2C-B that lasts longer.”
Too simplistic. It is a distinct conformationally constrained molecule.

“2C-B-FLY and Bromo-DragonFLY are basically the same.”
False—and potentially dangerous.

“Bromo-DragonFLY fatalities prove genuine 2C-B-FLY is equally lethal.”
No. They prove the danger of mislabeling and related chemistry, not identical toxicity.

“No 2C-B-FLY toxicology cases means it is safe.”
False. Sparse surveillance is not a safety trial.

“A negative routine drug screen rules it out.”
False.

Evidence ledger

Related evidence

• 25I-NBOMe
• 5-APB
• 6-MAPB
• 1P-LSD
• 1cP-LSD
• AL-LAD
• RC psychedelics evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

2C-B-FLY is a real, analytically confirmed serotonergic psychedelic with meaningful receptor/metabolism data and remarkably little direct human clinical evidence.

The most important real-world lesson is not a duration or dose claim.

It is that 2C-B-FLY has been confused with—or replaced by—Bromo-DragonFLY, a substantially different compound with severe vasoconstrictive and fatal toxicity.

A trustworthy reference must keep those drugs separate and keep the human evidence gap visible.